Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00948090 · ClinicalTrials.gov registry record · Phase 2
PK-directed Dose Adjustment of IV Busulfan Conditioning Regimen for Autologous Stem Cell Transplant in Lymphoma Patients
A Phase 2 study of Lymphoma, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Completed
- Registry status
- Phase 2
- Development phase
- 207
- Enrollment target
- 20
- Study locations
NCT00948090 is a Phase 2 study of Lymphoma that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 207 participants, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (57% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT00948090, a Phase 2 study of Lymphoma, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 207 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a study for the outcome and safety of individualized busulfan dosing with cyclophosphamide and etoposide for patients preparing for a stem cell transplant to treat Non-Hodgkin or Hodgkin's Lymphoma.
Conditions Studied
Interventions
- DRUG IV Busulfan, Cyclophosphamide and Etoposide (BuCyE Regimen)
Study Locations (20)
California
- Alta Bates Summit Medical Center - Berkeley
- Scripps Clinic - La Jolla
- UCSD Medical Center BMT Program - La Jolla
- Cedars-Sinai Medical Center - Los Angeles
- Sutter Cancer Center - Sacramento
- University of California, Davis Medical Center - Sacramento
- University of California San Francisco Medical Center - San Francisco
Illinois
- University of Illinois Cancer Center - Chicago
- The University of Chicago - Chicago
- Loyola University Chicago - Maywood
Alabama
- University of Alabama in Birmingham - Birmingham
Arizona
- Arizona Cancer Center - Tucson
Colorado
- Rocky Mountain Cancer Centers - Denver
Florida
- Florida Hospital Cancer Institute - Orlando
Georgia
- Emory University - Atlanta
Indiana
- Bone Marrow and Stem Cell Transplant Program - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 207 participants |
| Start Date | 2010-01 |
| Est. Completion | 2013-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00948090
The ClinicalTrials.gov registry entry for NCT00948090 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 207 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (57% lower). The listed sponsor is Otsuka Pharmaceutical Development & Commercialization, which has 221 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which IV Busulfan, Cyclophosphamide and Etoposide (BuCyE Regimen) is the first listed.
NCT00948090 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Illinois, Alabama.
Frequently Asked Questions
What is clinical trial NCT00948090 about?
NCT00948090 is a clinical study titled "PK-directed Dose Adjustment of IV Busulfan Conditioning Regimen for Autologous Stem Cell Transplant in Lymphoma Patients". This is a study for the outcome and safety of individualized busulfan dosing with cyclophosphamide and etoposide for patients preparing for a stem cell transplant to treat Non-Hodgkin or Hodgkin's Lymphoma.
What is the current status of trial NCT00948090?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 207 participants. The study started on 2010-01. Estimated completion is 2013-06.
What conditions does trial NCT00948090 study?
This clinical trial studies the following conditions: Lymphoma.
What interventions are being tested in trial NCT00948090?
The interventions under investigation include: IV Busulfan, Cyclophosphamide and Etoposide (BuCyE Regimen) (DRUG).
Who is sponsoring clinical trial NCT00948090?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00948090 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
RECRUITING · Phase 2
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.